Amarantus BioScience Holdings, Inc.
AMBS · OTC
12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
|---|---|---|---|---|
| Revenue | $95 | $0 | $75 | $20,000 |
| % Growth | – | -100% | -99.6% | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | $95 | $0 | $75 | $20,000 |
| % Margin | 100% | – | 100% | 100% |
| R&D Expenses | $0 | $0 | $0 | $1 |
| G&A Expenses | $0 | $0 | $0 | $0 |
| SG&A Expenses | $363 | $148 | $702 | $1,671 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $363 | $148 | $702 | $1,672 |
| Operating Income | -$268 | -$148 | -$628 | $18,328 |
| % Margin | -281.1% | – | -840.7% | 91.6% |
| Other Income/Exp. Net | -$4,494 | -$10,048 | $0 | $49 |
| Pre-Tax Income | -$4,762 | -$10,196 | -$628 | $18,377 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$4,762 | -$10,196 | -$628 | $18,377 |
| % Margin | -4,995.2% | – | -840.7% | 91.9% |
| EPS | -0.008 | -0.022 | -0.002 | 0.068 |
| % Growth | 62.6% | -1,188.2% | -102.5% | – |
| EPS Diluted | -0.008 | -0.022 | -0.002 | 0.068 |
| Weighted Avg Shares Out | 579,607 | 465,107 | 368,407 | 269,920 |
| Weighted Avg Shares Out Dil | 579,607 | 465,107 | 368,407 | 269,920 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $228 | $237 | $206 | $172 |
| EBITDA | -$4,534 | -$9,959 | -$422 | $18,549 |
| % Margin | -4,755.6% | – | -564.5% | 92.7% |